Sanofi says it is working with its third-party manufacturing partner to make its recently approved factor VIII therapy Altuviiio available from April. Last week, the US Food and Drug Administration (FDA) approved Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], Sanofi’s factor VIII replacement therapy. The therapy has been described as a first-in-class treatment for the treatment of patients with hemophilia A, delivering a normal to near-normal factor activity levels (over 40%) for most of the week through a single dose.…